EP Wealth Advisors LLC Acquires 13,625 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

EP Wealth Advisors LLC grew its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 125.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,475 shares of the company’s stock after buying an additional 13,625 shares during the quarter. EP Wealth Advisors LLC’s holdings in Allogene Therapeutics were worth $69,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ALLO. Perceptive Advisors LLC acquired a new stake in shares of Allogene Therapeutics in the second quarter valued at about $6,349,000. Lynx1 Capital Management LP bought a new stake in shares of Allogene Therapeutics during the 2nd quarter worth approximately $5,192,000. Renaissance Technologies LLC grew its stake in shares of Allogene Therapeutics by 340.4% in the second quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after buying an additional 1,351,055 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Allogene Therapeutics by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after buying an additional 507,021 shares during the last quarter. Finally, TD Asset Management Inc raised its position in Allogene Therapeutics by 82.7% during the second quarter. TD Asset Management Inc now owns 799,340 shares of the company’s stock worth $1,862,000 after acquiring an additional 361,904 shares in the last quarter. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Stock Performance

ALLO opened at $1.89 on Monday. The stock has a fifty day moving average of $2.55 and a 200-day moving average of $2.58. The company has a market capitalization of $396.28 million, a P/E ratio of -1.21 and a beta of 0.83. Allogene Therapeutics, Inc. has a fifty-two week low of $1.83 and a fifty-two week high of $5.78.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALLO. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Piper Sandler dropped their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).